A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer

被引：48

作者：

Wu, Xiujuan ^{[1
]}

Tang, Peng ^{[1
]}

Li, Shifei ^{[1
]}

Wang, Shushu ^{[1
]}

Liang, Yueyang ^{[1
]}

Zhong, Ling ^{[1
]}

Ren, Lin ^{[1
]}

Zhang, Ting ^{[1
]}

Zhang, Yi ^{[1
]}

机构：

[1] Third Mil Med Univ, Southwest Hosp, Breast Dis Ctr, Chongqing 400038, Peoples R China

来源：

NATURE COMMUNICATIONS | 2018年 / 9卷

关键词：

PATHOLOGICAL COMPLETE RESPONSE; ARTERIAL CHEMOEMBOLIZATION; ANTITUMOR-ACTIVITY; CHEMOTHERAPY; DOCETAXEL; CARBOPLATIN; EPIRUBICIN; PACLITAXEL; CISPLATIN; DOXORUBICIN;

D O I：

10.1038/s41467-018-03210-2

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Currently, one sixth of triple-negative breast cancer (TNBC) patients who receive docetaxel (T) and epirubicin (E) as neoadjuvant chemotherapy achieve a pathologic complete response (pCR). This study evaluates the impact of adding lobaplatin (L) to the TE regimen. Here, we show data from 125 patients (63 TE and 62 TEL patients). Four patients did not complete all the cycles. Two-sided P values show that the addition of L (38.7% vs. 12.7%, P = 0.001) significantly increases the rate of pCR in the breast and the axilla (TpCR) and the overall response rate (ORR; 93.5% vs. 73.0%, P = 0.003). The occurrence of grade 3-4 anemia and thrombocytopenia is higher in the TEL group (52.5% vs. 10.0% and 34.4% vs. 1.7% respectively). These results demonstrate that the addition of L to the TE regimen as neoadjuvant chemotherapy improves the TpCR and the ORR rates of TNBC but with increased side effects.

引用

页数：8

共 50 条

[11] Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial [J].

Guo, Honghai ;

Ding, Ping'an ;

Sun, Chenyu ;

Yang, Peigang ;

Tian, Yuan ;

Liu, Yang ;

Lowe, Scott ;

Bentley, Rachel ;

Li, Yaru ;

Zhang, Zhidong ;

Wang, Dong ;

Li, Yong ;

Zhao, Qun .

FRONTIERS IN ONCOLOGY, 2022, 12

[12] A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer [J].

Hasegawa, Hirotaka ;

Shitara, Kohei ;

Takiguchi, Shuji ;

Takiguchi, Noriaki ;

Ito, Seiji ;

Kochi, Mitsugu ;

Horinouchi, Hidehito ;

Kinoshita, Takahiro ;

Yoshikawa, Takaki ;

Muro, Kei ;

Nishikawa, Hiroyoshi ;

Suna, Hideaki ;

Kodera, Yasuhiro .

GASTRIC CANCER, 2022, 25 (03) :619-628

[13] Anlotinib in Chinese Patients With Recurrent Advanced Cervical Cancer: A Prospective Single-Arm, Open-Label Phase II Trial [J].

Zhu, Jun ;

Song, Chunyan ;

Zheng, Zhong ;

Xia, Lingfang ;

Chen, Yanqiong ;

Ke, Guihao ;

Wu, Xiaohua .

FRONTIERS IN ONCOLOGY, 2021, 11

[14] Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial [J].

Earl, Helena M. ;

Hiller, Louise ;

Dunn, Janet A. ;

Blenkinsop, Clare ;

Grybowicz, Louise ;

Vallier, Anne-Laure ;

Abraham, Jean ;

Thomas, Jeremy ;

Provenzano, Elena ;

Hughes-Davies, Luke ;

Gounaris, Ioannis ;

McAdam, Karen ;

Chan, Stephen ;

Ahmad, Rizvana ;

Hickish, Tamas ;

Houston, Stephen ;

Rea, Daniel ;

Bartlett, John ;

Caldas, Carlos ;

Cameron, David A. ;

Hayward, Larry .

LANCET ONCOLOGY, 2015, 16 (06) :656-666

[15] Prospective Phase II Open-Label Randomized Controlled Trial to Compare Mandibular Preservation in Upfront Surgery With Neoadjuvant Chemotherapy Followed by Surgery in Operable Oral Cavity Cancer [J].

Chaukar, Devendra ;

Prabash, Kumar ;

Rane, Pawan ;

Patil, Vijay Maruti ;

Thiagarajan, Shivakumar ;

Ghosh-Laskar, Sarbani ;

Sharma, Shilpi ;

Pai, Prathamesh S. ;

Chaturvedi, Pankaj ;

Pantvaidya, Gouri ;

Deshmukh, Anuja ;

Nair, Deepa ;

Nair, Sudhir ;

Vaish, Richa ;

Noronha, Vanita ;

Patil, Asawari ;

Arya, Supreeta ;

D'Cruz, Anil .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (03) :272-+

[16] Phase II open-label study of sunitinib in patients with advanced breast cancer [J].

Yardley, Denise A. ;

Dees, E. Claire ;

Myers, Stephen D. ;

Li, Sherry ;

Healey, Paul ;

Wang, Zhixiao ;

Brickman, Marla J. ;

Paolini, Jolanda ;

Kern, Kenneth A. ;

Citrin, Dennis L. .

BREAST CANCER RESEARCH AND TREATMENT, 2012, 136 (03) :759-767

[17] Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer [J].

Yuan, Yuan ;

Lee, Jin Sun ;

Yost, Susan E. ;

Li, Sierra Min ;

Frankel, Paul H. ;

Ruel, Christopher ;

Schmolze, Daniel ;

Robinson, Kim ;

Tang, Aileen ;

Martinez, Norma ;

Stewart, Daphne ;

Waisman, James ;

Kruper, Laura ;

Jones, Veronica ;

Menicucci, Andrea ;

Uygun, Sahra ;

Yoder, Erin ;

van der Baan, Bastiaan ;

Yim, John H. ;

Yeon, Christina ;

Somlo, George ;

Mortimer, Joanne .

ONCOLOGIST, 2021, 26 (03) :E382-E393

[18] Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE) [J].

Meyer-Wilmes, P. ;

Huober, J. ;

Untch, M. ;

Blohmer, J. -U. ;

Janni, W. ;

Denkert, C. ;

Klare, P. ;

Link, T. ;

Rhiem, K. ;

Bayer, C. ;

Reinisch, M. ;

Bjelic-Radisic, V. ;

Zahm, D. M. ;

Hanusch, C. ;

Solbach, C. ;

Heinrich, G. ;

Hartkopf, A. D. ;

Schneeweiss, A. ;

Fasching, P. ;

Filmann, N. ;

Nekljudova, V. ;

Holtschmidt, J. ;

Stickeler, E. ;

Loibl, S. .

ESMO OPEN, 2024, 9 (05)

[19] A Phase II Trial of Neoadjuvant Chemotherapy with Genexol® (Paclitaxel) and Epirubicin for Locally Advanced Breast Cancer [J].

Lee, Jinsun ;

Kim, Jeryong ;

Chang, Eilsung ;

Choi, Woonjung ;

Lee, Kwangman ;

Yoon, Hyunjo ;

Jung, Sunghoo ;

Park, Minho ;

Yoon, Junghan ;

Kim, Sungyong .

JOURNAL OF BREAST CANCER, 2014, 17 (04) :344-349

[20] A multicenter, open-label, phase II trial of pemetrexed plus bevacizumab in elderly patients with previously untreated advanced or recurrent nonsquamous non-small cell lung cancer [J].

Yabuki, Yohei ;

Hanibuchi, Masaki ;

Takeuchi, Eiji ;

Haku, Takashi ;

Kanematsu, Takanori ;

Nishimura, Naoki ;

Toyoda, Yuko ;

Mitsuhashi, Atsushi ;

Otsuka, Kenji ;

Sato, Seidai ;

Goto, Hisatsugu ;

Yoneda, Hiroto ;

Ogino, Hirokazu ;

Nokihara, Hiroshi ;

Tsutomu, Shinohara ;

Nishioka, Yasuhiko .

THORACIC CANCER, 2023, 14 (32) :3232-3239

← 1 2 3 4 5 →